What is the P/E ratio of Elder Pharmaceuticals?

The latest standalone P/E ratio of Elder Pharmaceuticals as of 01-Jan-1970 is 0.00.

What is the P/B ratio of Elder Pharmaceuticals?

The latest standalone P/B ratio of Elder Pharmaceuticals as of 01-Jan-1970 is 0.13.

What is the 52-week high and low of Elder Pharmaceuticals?

The 52-week high of Elder Pharmaceuticals is Rs. 38.00 and the 52-week low is Rs. 37.10.

Elder Pharmaceuticals Ltd - Stock Valuation and Financial Performance

Name: Elder Pharmaceuticals
Brand: Elder Pharmaceuticals

BSE: 532322 | NSE: ELDERPHARM | Pharmaceuticals & Drugs | Small Cap

Place order

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on Elder Pharma

Based on:

Data

M-Cap below 100cr DeciZen not available

Elder Pharmaceuticals stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

0.00

Market Cap:

78 Cr.

52-wk low:

37.1

52-wk high:

Is an attractive stock to invest in?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of Elder Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Jun'13	Jun'14	TTM
ROCE % ⓘ	15.1%	15.5%	15.1%	15.9%	12.5%	12.5%	12.7%	13.1%	14.5%	16.9%	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	285	355	449	551	620	703	839	985	986	483	233
Sales YoY Gr.	-	24.4%	26.6%	22.7%	12.5%	13.4%	19.3%	17.4%	0.2%	-51%	-
Adj EPS ⓘ	12	21.1	28.4	36.6	27.4	31.2	36.2	43.2	37.6	-117.8	-30.2
YoY Gr.	-	75.7%	35%	28.6%	-25.2%	14.2%	15.9%	19.3%	-12.9%	-413.1%	-
BVPS (₹) ⓘ	124.2	146.3	172.8	203.9	220.2	251.7	297.6	336.8	303	382.5	299.2
Adj Net Profit ⓘ	19.2	36.8	52.8	68.8	51.6	58.9	74.3	88.6	77.3	-242	-62
Cash Flow from Ops. ⓘ	-10.3	-5.3	70.9	-37.4	62.2	8.9	61.8	19.5	-25.5	1,153	-
Debt/CF from Ops. ⓘ	-12.8	-37.6	3.3	-9.1	6.4	62.2	12.1	45.4	-35.7	0.5	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	6%	-4.9%	-16.8%	-51%
Adj EPS ⓘ	-228.9%	-233.9%	-248.2%	-413.1%
BVPSⓘ	13.3%	11.7%	8.7%	26.3%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Jun'13	Jun'14	TTM
Return on Equity % ⓘ	12.6	16.1	18.2	19.4	12.9	13.2	13.7	13.6	13.1	-30.9	-8.9
Op. Profit Mgn % ⓘ	14.7	17.1	17.4	19.1	16.3	18.4	21	20.6	21.8	-13.4	-95.3
Net Profit Mgn % ⓘ	6.7	10.4	11.8	12.5	8.3	8.4	8.9	9	7.8	-50	-26.7
Debt to Equity ⓘ	0.7	0.8	0.7	0.9	1	1.2	1.2	1.3	1.5	0.8	-
Working Cap Days ⓘ	261	243	231	212	232	250	257	281	327	755	415
Cash Conv. Cycle ⓘ	148	143	132	109	117	132	137	147	122	179	-82

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Elder Pharmaceuticals Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-30.2	-38.9
TTM Sales (₹ Cr.)	233	631
BVPS (₹.) ⓘ	299.2	290.6
Reserves (₹ Cr.) ⓘ	594	576
P/BV ⓘ	0.13	0.13
PE ⓘ	0.00	0.00

From the Market
52 Week Low / High (₹)	37.10 / 38.00
All Time Low / High (₹)	20.35 / 474.00
Market Cap (₹ Cr.)	78
Equity (₹ Cr.)	20.5
Face Value (₹)	10
Industry PE ⓘ	43

Management X-Ray of Elder Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

99.42

99.17

95.30

91.49

89.94

77.73

77.56

85.06

84.73

84.69

* Pledged shares as % of Promoter's holding (%)

Valuation of Elder Pharma

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Elder Pharma

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Jun'13	Jun'14
Sales	285.34	354.83	449.25	551.20	620.02	702.79	838.59	984.69	1,233.10	483.47
Operating Expenses ⓘ	243.45	294.23	371.25	445.87	520.65	578.19	662.78	782.53	964.03	571.58
Manufacturing Costs	19.42	31.63	35.54	43.41	44.82	50.66	35.38	39.98	47.33	34.19
Material Costs	144.79	160.87	203.20	244.62	278.97	304.54	368.66	471.35	573.09	308.35
Employee Cost	31.37	40.90	55.89	67.21	83.37	90.67	104.33	108.98	151.43	112.39
Other Costs ⓘ	47.87	60.84	76.62	90.63	113.50	132.31	154.40	162.22	192.17	116.65
Operating Profit ⓘ	41.89	60.60	78	105.33	99.37	124.61	175.81	202.16	269.07	-88.10
Operating Profit Margin (%)	14.7%	17.1%	17.4%	19.1%	16.0%	17.7%	21.0%	20.5%	21.8%	-18.2%
Other Income ⓘ	6.54	5.93	7.46	7.59	8.14	7.63	8.04	24.31	26.22	15.13
Interest ⓘ	14.02	14.13	15.58	23.73	37.39	50.78	62.90	89.02	137.97	260.06
Depreciation ⓘ	4.17	5.55	8.79	10.61	11.52	16.77	26.87	27.64	36.52	29.16
Exceptional Items ⓘ	0	0	0	0	0	0	-5.01	-6.29	-5.09	380.04
Profit Before Tax ⓘ	30.24	46.85	61.10	78.58	58.59	64.68	89.07	103.51	115.70	17.85
Tax ⓘ	9.85	10.15	8.33	9.93	7.95	9.29	18.28	19.44	21.97	9.93
Profit After Tax	20.39	36.70	52.77	68.65	50.64	55.39	70.79	84.07	93.74	7.92
PAT Margin (%)	7.1%	10.3%	11.7%	12.5%	8.2%	7.9%	8.4%	8.5%	7.6%	1.6%
Adjusted EPS (₹)	12.8	21.0	28.4	36.5	26.9	29.4	34.5	40.9	45.6	3.9
Dividend Payout Ratio (%)	20%	12%	9%	7%	9%	10%	9%	7%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Jun'13	Jun'14
Equity and Liabilities
Shareholders Fund	198.75	255.58	320.99	383.12	415.33	474.67	611.12	691.76	777.83	785.59
Share Capital ⓘ	16.02	17.50	18.60	18.82	18.89	18.89	20.57	20.57	20.57	20.57
Reserves ⓘ	182.73	238.08	302.39	364.30	396.44	455.78	590.55	671.19	757.26	765.03
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	131.87	197.69	236.52	341.59	400.14	555.68	679.76	780.87	972.26	544.64
Long Term Debt	131.87	197.69	236.52	341.59	400.14	555.68	375.44	423.97	573.63	349.10
Short Term Debt	0	0	0	0	0	0	304.32	356.90	398.63	195.54
Trade Payables	23.14	29.49	39.11	32.71	32.30	37.87	44.31	43.83	68.06	33.83
Others Liabilities ⓘ	56.82	67.79	76.39	60.43	86.24	86.92	164.61	197.88	389.38	571.69
Total Liabilities ⓘ	410.58	550.55	673.01	817.84	934.01	1,155.13	1,499.80	1,714.34	2,207.53	1,935.74
Fixed Assets
Gross Block	82.08	113.37	172.38	211.53	224.87	535.40	570.94	630.07	642.97	599.80
Accumulated Depreciation	18.30	23.43	32.08	42.36	53.61	70.10	95.17	122.46	158.74	164.89
Net Fixed Assetsⓘ	63.78	89.94	140.30	169.17	171.26	465.31	475.77	507.61	484.23	434.91
CWIP ⓘ	29.25	94.92	137.19	163.36	252.15	65.74	93.03	191.01	268.36	304.26
Investmentsⓘ	45.13	42.76	37.53	61.89	3.93	19.68	10.87	21.09	3.90	3.73
Inventories	96.35	107.07	93.26	83.68	88.11	142.56	184.90	221.25	159.26	27.90
Trade Receivables	61.53	108.20	122.43	139.55	177.63	193.24	226.66	284.47	328.37	84.47
Cash Equivalents ⓘ	48.84	36.52	56.44	66.71	63.79	77.31	251.67	129.34	87.83	538.39
Others Assetsⓘ	65.70	71.15	85.86	133.49	177.14	191.30	256.89	359.57	875.58	542.09
Total Assets ⓘ	410.58	550.55	673.01	817.84	934.01	1,155.13	1,499.80	1,714.34	2,207.53	1,935.74

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Jun'13	Jun'14
Cash Flow From Operating Activity ⓘ	-10.29	-5.25	70.93	-37.44	62.15	8.93	61.82	19.48	-31.93	1,153.39
PBT ⓘ	30.24	46.85	61.10	78.58	58.59	64.68	89.07	103.51	120.79	-362.19
Adjustment ⓘ	11.55	13.33	16.76	26.42	41.97	64.40	82.77	100.46	144.28	668.69
Changes in Working Capital ⓘ	-28.31	-40.25	19.94	-109.51	8.58	-58.87	-91.41	-163.4	-272.5	856.16
Tax Paid ⓘ	-9.75	-11.06	-11.29	-9.20	-9.60	-10.50	-18.61	-21.09	-24.50	-9.26
Cash Flow From Investing Activity ⓘ	-50.66	-88.66	-88.59	-82.08	-37.50	-137	-47.42	-145.18	-48.17	-14.99
Capex	-34.37	-96.96	-101.29	-65.32	-102.13	-124.13	-64.65	-157.68	-90.50	-28.32
Net Investments	-22.84	2.37	5.23	-24.36	57.96	-15.75	8.80	-10.22	17.20	0.17
Others ⓘ	6.54	5.93	7.46	7.59	6.67	2.88	8.43	22.72	25.14	13.17
Cash Flow From Financing Activityⓘ	76.52	81.59	37.57	129.80	-27.57	141.59	159.97	3.36	38.59	-687.85
Net Proceeds from Shares ⓘ	80.11	26.67	21.64	7.54	0	0	69.70	0	0	0
Net Proceeds from Borrowing ⓘ	0.47	59.90	21	137.91	-21.59	147.11	62.14	48.54	149.66	-224.53
Interest Paid ⓘ	0	0	0	0	0	0	-59.29	-89.02	-137.97	-260.06
Dividend Paid ⓘ	-3.60	-4.37	-4.64	-4.66	-4.71	-4.71	-5.66	-6.16	-6.16	0
Others ⓘ	-0.47	-0.61	-0.42	-10.98	-1.27	-0.80	93.08	50.01	33.07	-203.25
Net Cash Flow ⓘ	15.56	-12.32	19.91	10.28	-2.92	13.52	174.36	-122.34	-41.50	450.55

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Jun'13	Jun'14
Ratios
ROE (%)	13.47	16.16	18.31	19.5	12.69	12.45	13.04	12.91	12.76	1.01
ROCE (%)	15.08	15.5	15.1	15.9	12.45	12.51	12.72	13.12	14.53	16.85
Asset Turnover Ratio	0.82	0.8	0.76	0.76	0.72	0.68	0.64	0.62	0.64	0.24
PAT to CFO Conversion(x)	-0.5	-0.14	1.34	-0.55	1.23	0.16	0.87	0.23	-0.34	145.63
Working Capital Days
Receivable Days	89	81	91	84	92	95	90	94	90	155
Inventory Days	102	97	79	57	50	59	70	75	56	70
Payable Days	72	60	62	54	43	42	41	34	36	60

Elder Pharmaceuticals Ltd Stock News

Elder Pharmaceuticals Ltd FAQs

What is the share price of Elder Pharma?

Company share prices are keep on changing according to the market conditions. The closing price of Elder Pharma on 01-Jan-1970 05:30 is ₹0.00.

What is the market cap of Elder Pharma?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Elder Pharma stood at ₹78.04.

What is the P/E ratio of Elder Pharma?

The latest P/E ratio of Elder Pharma as of 01-Jan-1970 05:30 is 0.00.

What is the P/B ratio of Elder Pharma?

The latest P/B ratio of Elder Pharma as of 01-Jan-1970 05:30 is 0.13.

What is the 52-week high and low of Elder Pharma?

The 52-week high of Elder Pharma is ₹38.00 and the 52-week low is ₹37.10.

What is the TTM revenue of Elder Pharma?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Elder Pharma is ₹232.8 ( Cr.) .

About Elder Pharmaceuticals Ltd

Elder Pharmaceuticals was incorporated in the year 1983 and commenced operations in 1989. The company is engaged into manufacturing and marketing of prescription pharmaceutical brands, surgical and medical devices.

Elder is one the leading companies in the pharmaceutical formulation market in India. It holds market leader position in three therapeutic segments - Womenâ€™s Healthcare, Wound Care and Nutraceuticals.

Products

Elder manufactures API and formulations spread across 4 manufacturing plants in India and one in Nepal. It manufactures various dosage forms like tablets, capsules, syrups, injectables, topical creams and ointments.

It manufactures wide range of pharmaceutical brands such as Thrive G, Formic, Carnitor, Tanatril, B-long, Cranbe, Bonviva etc.

Company Shelcal brand is one of the top brands in the Indian pharmaceutical industry.

Awards

The company was awarded Amity Corporate Excellence Award for the year 2008

Elder was also honoured Frost & Sullivan Market Leadership Award for its 'Shelcal' brand for the year 2008.

It was among the Forbes list of 'Asia's 200 Best under a billion' over a period of three years.

It has subsidiary namely Elder International FZCO in Dubai, Somerta Holdings Company in Cyprus and Elder Biomeda EDA in Bulgaria.

In 2012 - Joint Managing Director Mr Alok Saxena has been bestowed with â€œBrand Slam Leadership Awardâ€ on 13th Oct, 2012 by Indira Group of Institutes, Pune.
- Elder Pharma is awarded India's Most Admired Nutrition and Neutraceutical Company of the Year 2012
-Elder Pharmaceuticals Limited is awarded with CIO100 Award.
-Elder Pharma join hands with Swedish firm Sterisol AB